ADCT
ADC Therapeutics S.A.
There isn't enough reported data to score ADCT yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ADCT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
ADCT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ADCT PE Valuation
ADCT has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ADCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect ADCT's losses to shrink, with revenue growing.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ADCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.53 | +$0.89 |
| Q2 2026 | -$0.67 | +$0.87 |
| Q1 2026 | -$1.06 | +$0.36 |
| Q4 2025 | -$1.21 | +$0.41 |
| Q3 2025 | -$1.42 | +$0.97 |
| Q2 2025 | -$1.54 | +$1.01 |
| Q1 2025 | -$1.42 | +$1.33 |
| Q4 2024 | -$1.62 | +$1.30 |
ADCT has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ADCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $21.7M | +32% |
| Q2 2026 | $19.2M | +2.2% |
| Q1 2026 | $20.9M | -9.5% |
| Q4 2025 | $23.1M | +36% |
| Q3 2025 | $16.4M | -11% |
| Q2 2025 | $18.8M | +8.2% |
| Q1 2025 | $23M | +28% |
| Q4 2024 | $16.9M | +0.7% |
ADCT's revenue is recovering but still below its 2022 peak: $22M last quarter, up 32% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -66% | +122 points |
| Q2 2026 | -132% | +102 points |
| Q1 2026 | -121% | +2.5 points |
| Q4 2025 | -78% | +114 points |
| Q3 2025 | -189% | +4.1 points |
| Q2 2025 | -234% | -68 points |
| Q1 2025 | -124% | +63 points |
| Q4 2024 | -192% | +46 points |
ADCT's operating margin was −66% last quarter, up 122 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ADCT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ADCT on profitability, with a higher operating margin.
ADCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$27.9M | +$1.8M |
| Q2 2026 | -$11.8M | +$12.3M |
| Q1 2026 | -$29.7M | +$26.9M |
| Q4 2025 | -$31.1M | -$9.2M |
| Q3 2025 | -$29.6M | -$4.4M |
| Q2 2025 | -$24.1M | +$8.8M |
| Q1 2025 | -$56.6M | -$12M |
| Q4 2024 | -$21.9M | +$11.1M |
ADCT has burned cash in almost every quarter: −$101M over the past year, against −$132M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ADCT on cash generation, producing positive trailing cash flow while its opponent burns cash.
ADCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +394K shares |
| 1 year | +14% | +19M shares |
| 3 years | +89% | +73.2M shares |
| 5 years | +103% | +78.7M shares |
| Available history | +112% | +82.2M shares |
ADCT has 155M diluted shares, up 14% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | $218,871 |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ADCT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ADCT Net Leverage
ADCT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ADCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 61.0 | Neutral |
ADCT's weekly RSI is 44 (neutral) and its Stochastic is 61 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ADCT PE vs Healthcare Sector
ADCT has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ADCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.44 | 2.1% below |
| 20 week MA | $1.26 | 12% above |
| 50 week MA | $2.55 | 45% below |
| 100 week MA | $2.60 | 46% below |
| 200 week MA | $2.64 | 47% below |
ADCT has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ADCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.7 | $37.0 | +25% |
| 2021 | $37.0 | $21.3 | -43% |
| 2022 | $21.3 | $3.52 | -83% |
| 2023 | $3.52 | $1.66 | -53% |
| 2024 | $1.66 | $2.03 | +22% |
| 2025 | $2.03 | $3.51 | +73% |
| 2026 YTD | $3.51 | $1.41 | -60% |
ADCT has finished lower in three of the last six years. It's down 60% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over ADCT on returns for 2026, with the stronger performance.